A Phase I Study of TP-3654 in People with Myelofibrosis

Full Title

A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Purpose

The purpose of this study is to find the highest dose of the investigational drug TP-3654 that can be given in people with myelofibrosis that persists despite treatment. Myelofibrosis happens when bone marrow cells called fibroblasts make too much fibrous (scar) tissue and the bone marrow is not able to make enough normal blood cells. TP-3654 blocks enzymes that help the abnormal cells to survive, which may cause these cells to die and slow or stop myelofibrosis. TP-3654 is taken orally (by mouth).

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Tamanna Haque at 646-608-4166 or email [email protected].